Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $99,219 | $81,504 | $65,846 | $71,360 |
| % Growth | 21.7% | 23.8% | -7.7% | – |
| Cost of Goods Sold | $8,685 | $7,492 | $8,830 | $6,905 |
| Gross Profit | $90,534 | $74,012 | $57,016 | $64,455 |
| % Margin | 91.2% | 90.8% | 86.6% | 90.3% |
| R&D Expenses | $19,604 | $19,453 | $17,543 | $14,480 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $62,404 | $69,170 | $64,002 | $57,607 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $82,008 | $88,623 | $81,545 | $72,087 |
| Operating Income | $8,526 | -$14,611 | -$24,529 | -$7,632 |
| % Margin | 8.6% | -17.9% | -37.3% | -10.7% |
| Other Income/Exp. Net | -$1,036 | -$933 | -$252 | -$2,833 |
| Pre-Tax Income | $7,490 | -$15,544 | -$24,781 | -$10,465 |
| Tax Expense | $80 | $342 | $279 | $323 |
| Net Income | $7,410 | -$15,886 | -$25,060 | -$10,788 |
| % Margin | 7.5% | -19.5% | -38.1% | -15.1% |
| EPS | 0.06 | -0.13 | -0.2 | -0.089 |
| % Growth | 146.2% | 35% | -124.2% | – |
| EPS Diluted | 0.06 | -0.13 | -0.2 | -0.089 |
| Weighted Avg Shares Out | 127,623 | 126,997 | 126,037 | 120,958 |
| Weighted Avg Shares Out Dil | 132,885 | 126,997 | 126,037 | 120,958 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3,071 | $3,029 | $2,982 | $5,551 |
| Depreciation & Amortization | $562 | $563 | $3,132 | $458 |
| EBITDA | $11,123 | -$11,952 | -$18,667 | -$4,456 |
| % Margin | 11.2% | -14.7% | -28.3% | -6.2% |